Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

NCT00528242 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Raynaud's Disease

Interventions

DRUG: SLx-2101
DRUG: Placebo

Sponsor

Response Pharmaceuticals